Latest Breaking News On - American society of clinical oncology plenary series - Page 1 : comparemela.com

GSK shares positive results for Blenrep combination in head-to-head multiple myeloma study

GSK shares positive results for Blenrep combination in head-to-head multiple myeloma study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesJohnson darzalexHesham abdullahTakeda velcadeAmerican society of clinical oncology plenary seriesAmerican societyClinical oncology plenary seriesVice president

Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib

Significant improvement in PFS, but not OS, versus chemo alone in the second-line setting

United statesFlorian lordickCharles bankheadRui hua xuAmerican society of clinical oncology plenary seriesSun yat sen university cancer centerUniversity cancer center leipzigAmerican societyClinical oncology plenaryMedpage today

NCCN Recommends Krazati for Treatment of Pancreatic Cancer Subset

The National Comprehensive Cancer Network updated its recommendations to include Krazati for patients with KRAS G12-mutant pancreatic cancer.

United statesNational comprehensive cancer networkUniversity of texas md anderson cancer centerAmerican society of clinical oncology plenary seriesShubham pantCancer centerAmerican societyClinical oncologyPlenary seriesRapid communicationPractice guidelines

BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer

The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.

Li zhangUnited statesRobert haddadJunshi bioscienceMerck keytrudaBristol myers squibb opdivoAmerican society of clinical oncology plenary seriesDrug administrationSun yat sen university cancer centerOncology congressEuropean society for medical oncology immunoOncology panelDana farber cancer instituteNational comprehensive cancer networkAmerican societyClinical oncology plenary series

Ripretinib Safer Than Sunitinib for GIST, Fails to Improve PFS

The findings suggest that ripretinib (Qinlock) provides a similar PFS benefit but may come with notably better tolerability compared with sunitinib.

United statesDana farber cancer instituteMichaelc heinrichAmerican society of clinical oncology plenary seriesTheseus pharmaceuticalsOregon health science universityHarvard medical schoolDeciphera pharmaceuticalsSarcoma center at dana farber cancer instituteOregon healthScience universityAmerican societyClinical oncology plenarySarcoma centerHarvard medicalBlueprint medicines